The co-chaperone protein, BAG3, which belongs to the BAG protein family, has an established antiapoptotic function in different tumor cell lines. Here we demonstrated that treatment of the human neuroblastoma cell line, SK-N-MC, with fibroblast growth factor-2 (FGF-2) results in induction of BAG3 expression. Induction of BAG3 protein by FGF-2 occurs at the transcriptional level; it requires the extracellular regulated kinase1/2 pathway and is dependent on the activity of Egr-1 upon the BAG3 promoter. Targeted suppression of BAG3 by small-interfering RNA results in dysregulation of cellcycle progression most notably at S and G 2 phases, which corroborates the decreased level of cyclin B1 expression. These observations suggest a new role for BAG3 in regulation of the cell cycle.
Introduction
Fibroblast growth factor-2 (FGF-2) has been reported to be important in the development and function of numerous organ systems, promoting proliferation and differentiation of a wide range of cell types. Angiogenesis, hematopoiesis, chondrogenesis, myogenesis, wound healing and tissue repair are among the biological events that are regulated by FGF-2 (Basilico and Moscatelli, 1992; Schwartz and Liaw, 1993; Bikfalvi et al., 1997) . FGF-2 also has numerous effects on the nervous system, which span from regulation of stem cell proliferation and differentiation to neuronal survival (Gremo and Presta, 2000) . Moreover, FGF-2 is widely expressed in the embryonic central nervous system (CNS) (Baird, 1994) , and has been shown to have a mitogenic action on a variety of forebrain CNS progenitor cells (Temple and Qian, 1995; Gritti et al., 1996) . FGF-2 is intimately involved in neuronal protection and repair after ischemic or traumatic brain injury; it prevents apoptosis by activating antiapoptotic pathways and promotes neurogenesis in the adult hippocampus after injury (Alzheimer and Werner, 2002) .
Egr-1 is a zinc-finger transcription factor that responds rapidly to a variety of stimuli and functions as a convergence point for many signaling cascades and couples short-term extracellular signals to longer-term changes in the expression of target genes (reviewed by Thiel and Cibelli, 2002) . It has been reported that Egr-1 is closely linked to FGF-2 signaling and has been implicated in orchestrating changes in gene expression that underlie neuronal plasticity and brain development (O'Donovan et al., 1999; Midgley and Khachigian, 2004) . Here we report the involvement of BAG3 in these events.
The human BAG family of proteins comprises six family members (BAG1-6) that are thought to function as molecular chaperone regulators (Doong et al., 2002) . Recent evidence has demonstrated that a member of the BAG protein family, BAG1, has an essential role in differentiation and survival of neuronal cells in vivo (Gotz et al., 2005) and mediates neuroprotectivity (Liman et al., 2005) . The BAG protein family, whose members share a highly conserved BAG domain, has been shown to participate in a wide variety of cellular processes including cell survival (stress response), proliferation, migration and apoptosis (Doong et al., 2002) . By interacting with the ATPase domain of Hsc70/ Hsp70, BAG proteins modulate their activity in physiological and stress conditions. Some BAG proteins have been demonstrated to inhibit Hsc70/Hsp70 chaperone activity in vitro (Takayama et al., 1999) . BAG1, 3 and 4 have also been isolated as Bcl-2-binding proteins (Bcl-2-associated AthanoGene) (Lee et al., 1999) . Despite their common C-terminal BAG domain, BAG proteins differ widely in their N termini, whose features should confer different properties and functions to each member.
BAG3, also known as Bis or CAIR-1, is the only member having a WW domain, which has not yet been linked to a particular function of this protein. The PXXP proline-rich motif, also present in BAG6, mediates the interaction of BAG3 with the SH3 domain of PLC-g (Doong et al., 2000) . As do other BAG proteins, BAG3 binds to the ATPase domain of Hsc70 with high affinity and inhibits its chaperone activity in a Hip-repressible manner (Takayama et al., 1999; Rosati et al., 2007a) . Furthermore, BAG3 has a synergistic effect on the antiapoptotic activity of Bcl-2 (Lee et al., 1999) . With respect to cancer, BAG3 has been found to be overexpressed in pancreatic and thyroid tumors (Liaoa et al., 2001; Chiappetta et al., 2007) and it is thought that it exerts a prosurvival effect in chronic lymphocytic leukemia and acute lymphoblastic leukemia primary cultures (Romano et al., 2003a, b) . Knockout of the BAG3 gene in the mouse leads to a fulminant myopathy and an early lethality and has unveiled new roles for this protein (Homma et al., 2006) . Notably, it has been also observed that BAG3 expression can be induced by some stressful agents such as high temperatures and heavy metals (Pagliuca et al., 2003) , and HIV-1 infection (Rosati et al., 2007b) . However, little is known about the role of BAG3 in nervous system.
In light of observations demonstrating the effect of FGF-2 on Egr-1 activity and the presence of potential Egr-1-binding site on the BAG3 promoter, we initiated studies to assess the impact of FGF-2 on BAG3 expression in SK-N-MC cells, a neuroblastoma cell line that is responsive to FGF-2.
In the present study, we show that BAG3 expression is induced by FGF-2 in human neuroblastoma cells, SK-N-MC. The signaling cascade required for this event is the mitogen-activated protein kinase (MEK)/extracellular regulated kinase (ERK) pathway, which activates the transcription factor Egr-1. Egr-1 activity is then exerted on BAG3 promoter through two Egr-1-binding sites. Furthermore, BAG3 induction due to FGF-2 affects cell progression through S/G 2 phases of the cell cycle.
Results
Little is known about the role of BAG3 in the CNS and less has been found on its effect on the growth of cells of neuroectodermal origin. Here, we utilized a human neuroepithelioma cell culture model, SK-N-MC, to investigate the expression of BAG3 and its possible role in cell growth and differentiation. Earlier studies showed that treatment of SK-N-MC cells with FGF-2 results in morphological changes associated with the formation of dendrites and processes. The extent of these changes is noticeably diminished upon pretreatment of cells with the MEK inhibitor U0126 (Kim et al., 2004) . Examination of BAG3 in these cells revealed a substantial increase in the level of this protein in cells that were maintained in 2% serum overnight followed by FGF-2 treatment for 24 h. Interestingly, ERK1/2 inhibition blocked FGF-2-mediated enhancement of BAG3, whereas inhibition of JNK, a pathway that is involved in apoptosis of neuroblastomas at later stages of cell treatment with FGF-2, showed no impact on the induced level of BAG3 in these cells (Figure 1a) . Further, activation of BAG3 upon FGF-2 treatment is concurrent with the increased level of phosphorylated ERK1/2 (Figure 1b) . Similar results were obtained in cells maintained in serum-free media followed by FGF-2 treatment (data not shown). As a first step toward understanding the mechanism underlying BAG3 activation by FGF-2, we performed RNA analysis from the cells after FGF-2 treatment in the absence and presence of the U0126 inhibitor. Results depicted in Figure 1c show enhancement of BAG3 mRNA in cells upon treatment with FGF-2, which can be suppressed by MEK inhibitor. These observations suggest that FGF-2 stimulates transcription of BAG3 in SK-N-MC cells via the MEK pathway.
Next, we examined the activity of the BAG3 promoter in SK-N-MC cells under various conditions as indicated in Figure 2a . Treatment of the cells with FGF-2 enhanced the activity of the BAG3 promoter, and in 
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A Gentilella et al agreement with the results shown in Figure 1 , this induction is suppressed by MEK inhibition, but not JNK inhibition. We created a series of reporter constructs, containing various regions of the human BAG3 promoter and examined their responsiveness to FGF-2 treatment in SK-N-MC cells. As illustrated in Figure 2b , removal of the sequence spanning nucleotides À969 to À205, with respect to the transcription start site at þ 1, had only minimal effect on the level of FGF-2 activation of the BAG3 promoter. Removal of the DNA sequence between À205 to À26 completely abrogated FGF-2 responsiveness of the BAG3 promoter and also decreased the basal level of BAG3 transcription ( Figure 2b ). Examination of the FGF-2 promoter sequence spanning À205 to À27 by Match algorithm with Transfac matrices revealed the presence of two separate Egr-1-binding sites at distal (À150 to À142) and proximal (À50 to À42) positions with respect to the transcription start site, and one Elk-1-binding site spanning nucleotides À187 to À183. This is an interesting notion in light of the earlier observations showing that both Egr-1 and Elk-1 can be activated by FGF-2 in various cell lines (Carreras et al., 2001; Kontaridis et al., 2002; Vogel et al., 2006) . To assess the contribution of these two domains in the activation of BAG3 promoter by FGF-2, a mutation that alters nucleotide composition of either or both domains was introduced and the transcriptional activity of these mutant promoters in response to FGF-2 was evaluated. As shown in Figure 2c , the level of BAG3 activation by FGF-2 was slightly decreased from the promoters containing a mutation in either the proximal or distal Egr-1-binding sites. Combined activation in both proximal and distal domains showed more impact on the responsiveness of the BAG3 promoter to FGF-2 induction. These observations indicate that the Egr-1-binding sites are important for full induction of BAG3 by FGF-2.
To investigate the in-vivo interaction of Egr-1 with the BAG3 DNA sequence spanning À205 to À27, we performed chromatin immunoprecipitation (ChIP) assay. As shown in Figure 3a , we observed a noticeable increase in the intensity of the DNA band pointing to enhanced in-vivo interaction of Egr-1 with the BAG3-promoter DNA sequence upon treatment of the cells with FGF-2 (compare lanes 1 and 2). Exposure of the cells to MEK inhibitor suppressed the elevated levels of Egr-1-binding to BAG DNA. The absence of amplified DNA fragments from immunocomplexes obtained from normal rabbit serum and the equal level of DNA amplification from the input DNA verified the specificity of this observation and equal loading and efficiency of DNA amplification. To further investigate the association of Egr-1 with the proximal and distal Egr-1-binding sites of the BAG3-promoter upon FGF-2 treatment, we performed band shift assays using nuclear extracts prepared from SK-N-MC cells under various conditions. As shown in Figure 3b , a new DNA protein complex (Cx) was detected when protein extracts from FGF-2-treated cells were incubated with DNA probes corresponding to the distal or proximal Egr-1-binding sites. Treatment of the cells with U0126 negated At 24 h after transfection, the cells were treated with FGF-2 and the inhibitors for 20 h after which cells were harvested and luciferase and renilla assays were performed. The data are expressed as fold effect from three independent assays where luciferase activity was normalized with renilla expression. (b) Transcription activation of deletion mutants of the BAG3 promoter in FGF-2 treatment in SK-N-MC cells positions. Positions and nucleotide composition of two GC-rich domains located between À150 and À142 (Dist.) and À50 to À42 (Prox.) are shown. Fold activation was determined from three independent experiments after normalization with renilla activity. (c) Transcriptional activation of the BAG3 promoter (À201/ þ 306) and its mutant variants with alterations at the proximal Egr-1-binding site (nucleotides À50 to À42) (Mut. Prox.), distal-binding site (nucleotides À150 to À142) (Mut. Dist) or both sites, Mut. Prox. þ Dist. Fold activation was determined from three independent experiments. The asterisks represent Po0.01. Dist., distal; Prox., proximal; Mut., mutation.
BAG3 regulation by FGF-2 A Gentilella et al formation of this complex. Further, mutant DNA probes derived from proximal and distal Egr-1 with altered Egr-1-binding sites failed to form a Cx complex (Figure 3b) . Treatment of the binding reaction with antiEgr-1 antibody, but not with normal rabbit serum, resulted in supershift DNA protein complex suggesting the presence of Egr-1 in the Cx complex (Figure 3c ). These observations verify the ability of Egr-1 to specifically associate with both distal and proximal Egr-1-binding sites within the BAG3 promoter. Of note, from the intensity of the band it appears that under similar experimental conditions the proximal-binding site has a stronger binding affinity than the distalbinding site to Egr-1 (Figure 3b, compare lanes 2 and 8) .
Results from similar studies with a DNA probe containing À187 to À183 sequence of the BAG3 promoter showed no evidence for the association of Elk-1 with BAG3 DNA (data not shown).
In the next series of experiments, we asked whether treatment of SK-N-MC cells with FGF-2 impacts on the level of Egr-1 and hence BAG3 expression. To this end, cells were treated with FGF-2 and at various times after treatment, cell extracts were prepared and tested for Egr-1 expression by western blot analysis. As seen in Figure 4a , a significant increase in the level of Egr-1 was observed 1 h after treatment of cells with FGF-2 and remained constant up to 4 h. Our subsequent study showed that Egr-1 levels remained high for up to 16 h following treatment (data not shown). To directly correlate FGF-2 induction of Egr-1 with BAG3 expression, cells were treated with Egr-1-targeted smallinterfering RNA (siRNA) and after 24 h they were treated with FGF-2 before harvesting for protein assay. As shown in Figure 4b , treatment of cells with Egr-1-specific siRNA, but not control nonspecific siRNA, diminished the level of BAG3 induction by FGF-2. As anticipated, the level of Egr-1, but not the housekeeping a-tubulin, protein was decreased by Egr-1 siRNA. Activation of BAG3 by FGF-2 was also observed in another neuroblastoma cell line, SH-SY-5Y and in PC12 cells, a cell line derived from rat with the ability to differentiate toward neuronal lineage. In contrast, Figure 3 Egr-1 interacts with BAG3 promoter in response to fibroblast growth factor-2 (FGF-2). (a) Chromatin immunoprecipitation (ChIP) assay. SK-N-MC incubated with FGF-2 (pretreated with U0126 where indicated) for 16 h were formaldehyde-cross-linked, and chromatin was immunoprecipitated with anti-Egr-1 or normal rabbit serum, followed by PCR amplification with BAG3-promoterspecific primers and analysed by Southern hybridization with Egr-1 probe. Input genomic DNA was used as positive control. (b) Nuclear extracts from SK-N-MC cells, which were either unstimulated (lanes 1-4 and 7-10), treated with FGF-2 alone (lanes 2-5 and 8-11) and in presence of mitogen-activated protein kinase kinase (MEKK) inhibitor (lanes 3-6 and 9-12) were subjected to electrophoretic mobility shift assay (EMSA), using as probe the two putative Egr-1-binding sites (distal site and proximal site) from the BAG3-promoter region responsive to FGF-2. (c) Gel supershift assays were performed with specific anti-Egr-1 antibody or normal rabbit serum as described in 'Materials and methods' with nuclear extract from untreated or FGF-2-treated cells. Arrows point to the position of the Egr-1 complex whereas the asterisk indicates a nonspecific complex. The asterisks represent a non-specific band.
A Gentilella et al FGF-2 treatment of MCF-7 cells, which are derived from mammary gland carcinoma and are responsive to FGF-2, had no effect on BAG3 levels (data not shown).
To investigate the impact of BAG3 induction by FGF-2 on cell growth and proliferation, cells were transfected with BAG3 siRNA then maintained in media containing aphidicholine (5 mM) and 2% serum for 16 h. Distribution of cells in cell-cycle stages was assessed by fluorescence-activated cell sorting analysis. As shown in Figure 5a , in control cells (transfected with nonspecific siRNA), FGF-2 treatment increased cell accumulation at G 2 /M from 36.1-50% (black bars). At the same time, the appearance of cells at S phase was slightly reduced (from 16.3 to 11.2%) (light gray bars). Treatment of the cells with BAG3-specific siRNA, which caused a nearly 50% decrease in the level of BAG3 in the presence of FGF-2 (Figure 5b , middle panel), altered distribution of cells in G 2 /M and S phases in the presence of FGF-2. As shown in Figure 5a , only 40.6% of the cells were accumulated in G 2 /M phase whereas 17.7% of the cells were detected in S phase. Thus, as seen, suppression of BAG3 levels upon FGF-2 treatment decreased (19.8%) of the cell distribution at G 2 /M and increased (58.0%) cell appearance at S phase. In the absence of FGF-2, cells transfected with BAG3 siRNA in the absence of FGF-2 showed no noticeable difference in G 2 /M distribution compared to that from control siRNA. Examination of the level of cyclin B1, a major regulator that orchestrates cell-cycle progression through the G 2 phase, was lowered in cells treated with BAG3 siRNA (Figure 5b ). These observations highlight the possible role of BAG3 on cell-cycle progression in response to FGF-2 by affecting S/G 2 checkpoint that results in the accumulation of cells at S phase, possibly controlling their entry into G 2 phase as a result of cyclin B1 expression.
Discussion
FGF-2 and Egr-1 are important in self-renewal of CNS progenitor stem cells (Temple and Qian, 1995; Gritti et al., 1996) . This process is of crucial importance during brain development and in response to injuries such as ischemia and seizure (O'Donovan et al., 1999; Lowe et al., 2003) . Our results demonstrate that BAG3 is a new target for FGF-2, and that activation of BAG3 upon treatment with FGF-2 is mediated by Egr-1. This is an interesting observation in light of other reports that Egr-1 is activated by several other growth factors including NGF and BDNF in different cellular contexts (Her et al., 2004; Ro¨ssler and Thiel, 2004) . Curiously, we observed that NGF does not have any effect on BAG3 expression in SK-N-MC, yet it stimulates BAG3 expression in PC12 cells (data not shown), suggesting that additional cellular factor(s) is involved in the activation of BAG3 by Egr-1 in various cell types. We also observed that BAG3 induction by FGF-2 impacts cell-cycle progression at S/G 2 . As previously reported, BAG1, through its BAG domain, interacts with and activates Raf-1 in a Ras-independent manner. This event, in turn, activates ERK1/2 and their downstream targets, leading to positive regulation of DNA synthesis (Song et al., 2001) . Due to the degree of homology among BAG domains of BAG1 and 3, one may anticipate that BAG3 binds and activates Raf-1 and its downstream pathways, thus modulating DNA synthesis. This is interesting in light of our observations BAG3 regulation by FGF-2 A Gentilella et al on the accumulation of cells at S phase of the cell cycle. BAG3 has also been reported to abrogate Hsp-70-mediated proteasomal degradation of client proteins as Akt, EGF-R and Raf-1 (Doong et al., 2003) . By sustaining the levels of these proteins, which are involved in growth and proliferation, BAG3 may affect FGF-2-mediated S/G 2 progression.
Induction of BAG3 by FGF-2 may have other impacts on cell behavior. For example, FGF-2 promotes differentiation of SK-N-MC cells toward a neuronallike phenotype. This event is associate with increased expression of neurofilament L and class III b-tubulin (Kim et al., 2004; Russo et al., 2004) . However, our preliminary results showed that suppression of BAG3 expression by siRNA has no impact on the expression of these neuronal markers upon FGF-2 treatment of the cells (data not shown). Despite the increase in G 2 /M population, FGF-2 treatment decreases the growth rate of SK-N-MC cells (Smits et al., 2000) . The induction of BAG3 expression by FGF-2 is not accountable for any change in proliferation rate in SK-N-MC (data not shown). Preliminary data in neural progenitor cells, on the other hand, suggest that in this cellular context BAG3 expression is sustained by FGF-2 has a proliferative effect.
In light of our new findings, we conclude that BAG3 is a new downstream effector of growth factors, in particular FGF-2, and its activity has a considerable effect on the progression of S/G 2 cell-cycle phases. This ascribes a new role for BAG3 in control of the cell cycle and proliferation, corroborating earlier observations demonstrating overexpression of BAG3 in a variety of cancer cells and its possible role in the response of tumor cells to chemotherapy-induced apoptosis (Romano et al., 2003a, b; Chiappetta et al., 2007) . However, the mechanism involved in this event remains to be investigated. On the other hand, the involvement of the MEK/ERK pathway in BAG3 upregulation provides a rationale for studying the impact of BAG3 in tumors that exhibit dysregulated MEK/ERK pathway. The level of BAG3 was elevated in the brain after transient forebrain/ischemia and seizure induced in experimental animals. These events are associated with a high level of FGF-2 expression in affected regions of the brain (Issa et al., 2005) . This implies a possible role for BAG3 in neural cell survival or repair (Lee et al., 2002a, b) . Creation of an experimental animal model with conditional expression of BAG3 in brain will provide important clues regarding the involvement of BAG3 in the development of brain and responses to stress and injury.
Materials and methods
Cell culture SK-N-MC are human neuroepithelioma cells that we obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA, USA). For FGF-2 treatment, cells were transferred to DMEM plus 2% fetal bovine serum (FBS) 16 h prior to the addition of human recombinant FGF-2 (Invitrogen) at a concentration of 40 ng/ml. (Basel, Switzerland) . Human recombinant FGF-2 was purchased from Invitrogen. Bradford Reagent was from Bio-Rad (Hercules, CA, USA). Polyclonal antibody to BAG3 (TOS-2) and monoclonal antibody to BAG3 (AC-1) were obtained from Alexis Biochemicals (San Diego, CA USA). A specific siRNA-targeting BAG3 mRNA (5 0 -AAGGUUCAGACCAUCUUGGAA-3 0 ) and a nonspecific siRNA (5 0 -CAGUCGCGUUUGCGACUGG-3 0 ) were purchased from Dharmacon, (LaFayette, CO, USA). BAG3 siRNA has been selected among three different BAG3-targeting siRNA sequences that have been evaluated for high specificity and lack of off target effect at the concentration used. Polyclonal anti-Egr-1 (588) was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Polyclonal antip42/p44 MAP kinases (137F5), polyclonal anti-phospho-p42/ p44 (Thr202/Tyr204) were from Cell Signaling Technology (Danvers, MA, USA). Anti-a-tubulin (clone B-5-1-2) was purchased by Sigma-Aldrich (St Louis, MO, USA). Goat anti-(mouse immunoglobulin G, IgG)-peroxidase conjugate and goat anti-(rabbit IgG)-peroxidase conjugate were from Pierce (Rockford, IL, USA).
Materials

Mutagenesis
Site-directed mutagenesis was performed in plasmid-containing À205/ þ 306 of the BAG3 promoter by PCR using the QuikChange II site-directed mutagenesis kit (Strategene, La Jolla, CA, USA) according to the supplier's protocol. The following nucleotides were used as primers for creating the nucleotide substitutions. Egr-1-binding sites are in bold and the altered nucleotides are underlined:
Protein analysis
Cell protein extracts were prepared as described previously (Zapata et al., 1998) and quantitated by Bradford Assay (BioRad). Cell protein extracts (15-20 mg) were resuspended in SDS-sample buffer and after treatment at 95 1C for 5 min, proteins were size-fractionated by 10% SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to nitrocellulose membranes. Blots were stained with Ponceau S to confirm equal loading and transfer of proteins and then reacted with the indicated antibodies. Immunoblots were developed using appropriate secondary horseradish peroxidase-coupled antibodies and an enhanced chemiluminescence plus kit (Pierce).
RNA analysis
Total cellular RNA (1.8 Â 10 5 cells per sample) was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Total RNA (12 mg) was resolved on BAG3 regulation by FGF-2 A Gentilella et al formaldehyde-containing 1.2% agarose gel and transferred to Hybond-N nylon membranes (GE Healthcare) and crosslinked by ultraviolet irradiation. A 823 bp Sal1/Xho1 DNA fragment corresponding to the BAG3-coding region was radiolabeled with [a-32 P]dCTP and used as a probe. The filter was prehybridized 1 h at 48 1C in UltraHyb solution (Ambion, Austin, TX, USA) and hybridized for 20 h at 48 1C with cDNA probe for BAG3 (10 6 c.p.m./ml). The blot was then rinsed twice 5 min with 2 Â SSC 0.1% SDS at 50 1C and washed twice with 0.2 Â SSC, 0.1% SDS at 50 1C for 20 min. The filter was exposed at À80 1C to Fuji XAR-5 film with Kodak intensifying screen. To verify equivalent RNA loading on northern blot membrane, the filter was rehybridized with glyceraldehyde 3-phosphate dehydrogenase cDNA probe.
Transfection and luciferase assays
The SK-N-MC cells were transfected using Fugene 6 (Roche). Cells were plated at a density of 1.8 Â 10 5 cells per well in a sixwell plate 48 h prior to transfection. Transfection was performed according to the manufacturer's protocol with 2 mg of reporter plasmid and 250 ng of Renilla luciferase control plasmid (Promega, Madison, WI, USA) for 24 h. Following this period, the transfection mixture was removed and replaced with media with or without 40 ng/ml FGF-2 for 20 h. Cell extracts were subsequently prepared and assayed using the Dual Luciferase kit (Promega) as per the manufacturer's instructions. Luciferase activities were normalized to the Renilla control plasmid, and values shown are the mean of three independent experiments.
Electrophoretic mobility shift assay Nuclear extracts were prepared as described previously (Andrews and Faller, 1991) . Electrophoretic mobility shift assays (EMSAs) were performed by incubating 10 mg of nuclear extracts with [ 32 P]-end-labeled double-stranded oligonucleotide probes (5.4 Â 10 4 c.p.m.) in binding buffer containing 10 mM Tris (pH 7.5), 75 mM KCl, 10% glycerol, 0.1 mM EDTA, 2.5 mM MgCl 2 , 0.25 mM DTT and 1.0 mg poly(dI-dC) at 4 1C for 20 min. Supershifts were performed by adding 2.0 mg antibody to the extract 30 min prior to incubation with probe. Protein/DNA complexes were resolved on 6% polyacrylamide gel run in 0.5 Â TBE, at 170 V at room temperature. The primers used for mutagenesis were also used for EMSA.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays were performed using the ChIP assay kit (Upstate Biotechnology Inc., Lake Placid, NY, USA), following the manufacturer's instructions. Briefly, SK-N-MC were incubated in presence or absence of FGF-2 (pretreated with 15 mM U0126 as specified) for 16 h. Cells were harvested and treated with formaldehyde (final concentration 1%) to crosslink chromatin. Cell lysates were then prepared and sonicated on ice to break chromatin DNA to an average length of 500 bp. Cell lysates (from 10 6 cells per sample) were treated with Egr-1 antibody (2 mg). DNA amplification of the captured DNA immunocomplex was performed using primers complementary to the BAG3-promoter region harboring both putative Egr-1-binding sites. The primer sequences were 5 0 -GACGGCCCCAGTCCAGCTCG-3 0 as forward and 5 0 -CTGAGTCATCGGCTATAATCG-3 0 as reverse to generate a 204 bp amplification product. DNA samples were analysed by electrophoresis on 1.2% agarose gels, stained with ethidium bromide then transferred to Hybond N nylon membranes (Amersham Biosciences, Piscataway, NJ, USA). The filter was prehybridized 1 h at 42 1C with Ultrahyb (Ambion), then probed using 10 6 c.p.m./ml of Egr-1 PS oligo terminally labeled with T4 polynucleotide kinase (Roche) and [g- Cell-cycle analysis Cell-cycle analysis was performed using the Guava cell-cycle reagent protocol (Guava Technologies, Hayward, CA, USA). Briefly, SK-N-MC cells were grown overnight in 2% serum plus 5 mM aphidicholine DMEM then transfected with 100 nM BAG3 siRNA or nonspecific siRNA using Lipofectamine 2000. After 12 h, cells were maintained in DMEM containing 2% serum for additional 12 h prior to the addition of FGF-2. After 24 h, cells were harvested, fixed with 70% ethanol and treated for 20 min with Guava cell-cycle reagent. Samples were evaluated on Guava EasyCyte Mini System. The data are representative of three different experiments.
Statistical analysis
All statistical analyses have been done by STDEV and AVERAGE programs.
